Bluebird Bio Inc (BLUE) 159.49 $BLUE Forget Biogen, Buy

New Post Public Reply Private Reply Replies (0) Message Board

Jul 28, 2015 at 12:17 AM

Bluebird Bio Inc (BLUE) 159.49 $BLUE

Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), LGND: 102.55 (+0.46), AMGN: 165.54 (+6.95), REGN: 540.03 (-1.82), EXEL: 5.44 (-0.15), CELG: 132.56 (-2.34)

Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), NBIX: 49.34 (-2.16), ISIS: 53.68 (+0.53), SRPT: 32.00 (-0.63), RCPT: 227.09 (-0.91)

What's in bluebird bio's Pipeline That Has Investors So Excited?
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jul 19, 9:02AM CDT
Clinical-stage biotechnology company bluebird bio has been a stellar investment for early investors, with the stock up more than 500% since coming public in 2013. However, since bluebird has yet to bring a product to market, investors have been...
BLUE: 159.49 (+0.58)

Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.19 (+0.28), BLUE: 159.49 (+0.58), AMBA: 119.45 (-4.78), NFLX: 106.43 (-2.91), EYES: 14.36 (-0.09), AMZN: 531.41 (+1.99), ZIOP: 12.03 (-0.45), LNKD: 220.66 (-4.40), FB: 94.17 (-2.78), RCPT: 227.09 (-0.91), LBIO: 8.79 (-0.64), INTC: 28.35 (+0.29), ONTY: 3.35 (-0.15), CELG: 132.56 (-2.34)

Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.19 (+0.28), BLUE: 159.49 (+0.58), AMBA: 119.45 (-4.78), NFLX: 106.43 (-2.91), EYES: 14.36 (-0.09), AMZN: 531.41 (+1.99), ZIOP: 12.03 (-0.45), LNKD: 220.66 (-4.40), FB: 94.17 (-2.78), RCPT: 227.09 (-0.91), LBIO: 8.79 (-0.64), INTC: 28.35 (+0.29), ONTY: 3.35 (-0.15), CELG: 132.56 (-2.34)

An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.19 (+0.28), BLUE: 159.49 (+0.58), AMBA: 119.45 (-4.78), NFLX: 106.43 (-2.91), EYES: 14.36 (-0.09), AMZN: 531.41 (+1.99), ZIOP: 12.03 (-0.45), LNKD: 220.66 (-4.40), FB: 94.17 (-2.78), RCPT: 227.09 (-0.91), LBIO: 8.79 (-0.64), INTC: 28.35 (+0.29), ONTY: 3.35 (-0.15), CELG: 132.56 (-2.34)

Strong Finish Is Key for Market
at The Street - Mon Jul 13, 3:18PM CDT
But there's still the problem of limited upside momentum.
BLUE: 159.49 (+0.58), NFLX: 106.43 (-2.91), AMZN: 531.41 (+1.99), TDOC: 31.31 (-0.84), GUID: 9.35 (-0.30), CBM: 45.70 (-3.21), FB: 94.17 (-2.78), LBIO: 8.79 (-0.64), GOOGL: 658.27 (+3.50), MBLY: 58.79 (-1.60), AAPL: 122.77 (-1.73)

Market Action Is Good but the Chase Is Off
at The Street - Mon Jul 13, 11:53AM CDT
There should be a solid close, but it's dead in the meantime.
BLUE: 159.49 (+0.58), NFLX: 106.43 (-2.91), AMZN: 531.41 (+1.99), TDOC: 31.31 (-0.84), GUID: 9.35 (-0.30), CBM: 45.70 (-3.21), FB: 94.17 (-2.78), LBIO: 8.79 (-0.64), GOOGL: 658.27 (+3.50), MBLY: 58.79 (-1.60), AAPL: 122.77 (-1.73)

Stock-Picking Action Looks Good for Bulls
at The Street - Mon Jul 13, 9:17AM CDT
Players are happy to set Greece aside, at least temporarily.
BLUE: 159.49 (+0.58), NFLX: 106.43 (-2.91), AMZN: 531.41 (+1.99), TDOC: 31.31 (-0.84), GUID: 9.35 (-0.30), CBM: 45.70 (-3.21), FB: 94.17 (-2.78), LBIO: 8.79 (-0.64), GOOGL: 658.27 (+3.50), MBLY: 58.79 (-1.60), AAPL: 122.77 (-1.73)

Why Shares in Bluebird Bio Slumped By More Than 10% in June
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 08, 8:41AM CDT
A narrowing of its collaboration with biotech Goliath Celgene Corp led shares of bluebird bio to tumble 13.3% in June (via data from Capital IQ ). Casting aside CAR-T Bluebird bio and Celgene had previously been collaborating on the...
BLUE: 159.49 (+0.58), CELG: 132.56 (-2.34)

For The Record
at Investor's Business Daily - Mon Jul 06, 5:44PM CDT
For The Record: The ticker symbol of Bluebird Bio (BLUE) is BLUE. The symbol was wrongly identified in an ETFs story that ran July 2 on page A7.
BLUE: 159.49 (+0.58)

Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT

BLUE: 159.49 (+0.58), DRNA: 12.70 (-0.32), ALNY: 128.82 (-0.80), TKMR: 10.30 (unch), JUNO: 47.80 (-2.36), CELG: 132.56 (-2.34)

Critical Alerts For Seadrill, Health Net Inc., American Airlines, Horizon Pharma and bluebird bio Inc. Released By InvestorsObserver
PR Newswire - Mon Jul 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, HNT, AAL, HZNP and BLUE.
BLUE: 159.49 (+0.58), HZNP: 36.13 (-1.07), AAL: 40.14 (+0.51), SDRL: 8.28 (-0.37), HNT: 65.60 (-0.07)

Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
DoctoRx - at Seeking Alpha - Fri Jul 03, 10:12AM CDT

AGTC: 17.41 (-0.39), BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), GILD: 110.54 (-2.29), AZN: 32.71 (-33.05), AMGN: 165.54 (+6.95), JUNO: 47.80 (-2.36), SRNE: 23.70 (+0.19), XLRN: 28.50 (-1.32), CELG: 132.56 (-2.34)

Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 159.49 (+0.58), KITE: 68.86 (+0.14), ADMS: 26.15 (-0.65), ACHN: 8.28 (-0.41)

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
at The Street - Thu Jul 02, 11:54AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 159.49 (+0.58), GILD: 110.54 (-2.29), MNKD: 4.77 (-0.21), PBYI: 84.69 (-4.60), KERX: 7.66 (-0.18), CELG: 132.56 (-2.34)

Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 159.49 (+0.58), KITE: 68.86 (+0.14), CLLS: 34.87 (-0.70), JUNO: 47.80 (-2.36), CYAD: 56.74 (-1.93), CELG: 132.56 (-2.34)

Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.19 (+0.28), NFLX: 106.43 (-2.91), BLUE: 159.49 (+0.58), AMZN: 531.41 (+1.99), TSLA: 253.01 (-12.40), KITE: 68.86 (+0.14), LBIO: 8.79 (-0.64), JUNO: 47.80 (-2.36), EGRX: 91.23 (-1.99)

A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.19 (+0.28), NFLX: 106.43 (-2.91), BLUE: 159.49 (+0.58), AMZN: 531.41 (+1.99), TSLA: 253.01 (-12.40), KITE: 68.86 (+0.14), LBIO: 8.79 (-0.64), JUNO: 47.80 (-2.36), EGRX: 91.23 (-1.99)

Biotech Investors Should Read Bibliographies Of Chief Scientific Officers
Intrepid Investor - at Seeking Alpha - Tue Jun 30, 11:42AM CDT

BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), TBIO: 1.61 (-0.04), SGMO: 8.87 (-0.29), SRNE: 23.70 (+0.19), CELG: 132.56 (-2.34), VICL: 0.61 (-0.02), GILD: 110.54 (-2.29), SGEN: 48.06 (-0.37), AEZS: 0.19 (-0.02), REGN: 540.03 (-1.82)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ajman Tourism Department Hits Internal Audit Milestone

A Nod to Standards in Ajman's Tourism Department Folks, it's not every day you see a government department get this kind of spotlight in the internal audit arena, yet here we are. The Ajman Department of Tourism, Culture and Media has snagged Full Conformance with Internal Audit Quality Standards. That’s not just some random feather in their cap but a signal flare in...

Full Sail University Bags Billboard Music School Honor

Full Sail Scores a Billboard Nod — What's the Big Deal? Alright, Full Sail University just snagged a spot on Billboard Magazine's 2026 Top Music Business Schools list. That's no small fry, folks. This Florida institution has been carving out a niche in the music business education scene with a hands-on learning approach that hits the nail right on the head. The Recipe...

Aspen Dental Brings Comprehensive Care to Whiteville

Bringing Dentistry Closer to Home Now, Whiteville's dental game just got a power-up, with Aspen Dental setting up shop in town. This isn't just another practice popping up—it's a full-on dental hub offering everything from regular cleanings to emergency tooth fixes. And let’s face it, this area's diverse population needs it. The Man Behind the Chair Guess who’s at...

Protecting Your Family on Halloween: Safety Tips

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

Lupin Secures FDA Nod for Key Injectable Drug

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...

Raken Debuts Change Orders: A Game-Changer for Builds

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

Hexaware Teams with Anthropic for Game-Changing AI Move

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...

PrideStaff: 8 Years Strong on Franchise Times Top 400

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Mexico's Beaches Shine in 2026 Best America Rankings

Mexican Shores Turning Heads in 2026 This isn’t just another wave in tourism news; it’s a tidal shift towards Mexico’s sizzling beaches claiming some prime spots on the global travel stage. If you’ve got an eye for tourism dynamics, listen up because Mexico’s sun-soaked shores just snagged six spots among the top 20 beaches in the Americas, according to the...

Teamsters Secure Landmark Deal for SF Parking Workers

Major Win for San Francisco's Parking Professionals Parking lots and garages across San Francisco might not be the first places you’d look for labor triumphs, but that’s exactly what almost 1,000 members of Teamsters Local 665 have achieved. Under a newly ratified four-year master contract, these parking pros snagged one of the richest deals the industry has seen. A...